Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. 

It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms.


ICYMI Leader Board

Stocks highlighted in blue have made market-moving announcements (click headings to sort).

Wordpress Table Plugin

West Wits Mining (ASX:WW1) has made changes to its management and board of directors as it embarks on a new stage of growth at the Witwatersrand Basin Project (WBP) in South Africa with an updated DFS due in the coming weeks.

WWI says Jac van Heerden will transition from managing director to non-executive director, effective 31 July 2023 as he takes up a new position as general manager of a new copper-zinc-gold project in East Africa.

Following his move, Rudi Deysel will assume the role of chief operating officer and country manager (RSA).

The company has also appointed Keith Middleton as executive manager commercial.

Everest Metals (ASX:EMC) says Rio Tinto (ASX:RIO) is due to kick off a seven-hole, 1400m drill program over the North Rover JV this week.

The target is potential pegmatite hosted lithium mineralisation beneath weathered pegmatite outcrop.

“EMC is pleased Rio Tinto Exploration has decided to progress to the next stage of the North Rover earn-in with commencement of this drilling program,” CEO Simon Phillips says.

“It’s exciting to have a major earn-in partner in exploring this relatively underexplored part of the EMC portfolio.”

The program will take ~10 days to complete.

Rio can earn 80% in the non-gold mineral rights on North Rover by sole funding A$5m of non-gold exploration.

RareX (ASX:REE)’s proposed Stage 3 rare earths operation at its Cummins Range phosphate and REE project has received an economic boost from successful testwork which upgraded the total REE grade, making the leach residue far better suited for further processing to extract REEs.

And PharmAust (ASX:PAA) is set to proceed with the Phase 2 clinical trial of its lead drug candidate monepantel (MPL) in motor neurone disease following the receipt of further positive results – this time showing trial participants had significant reduced levels of p75ECD – a biomarker with predictive value in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS) progression.


At Stockhead we tell it like it is. While West Wits Mining, RareX, and PharmAust are Stockhead advertisers, they did not sponsor this article.